Press Releases

BALTIMORE, Mar 25, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (Nasdaq:OSIR) today announces positive six-month results in a groundbreaking clinical trial evaluating PROVACEL(TM), an adult mesenchymal stem cell (MSC) therapy for the treatment of heart disease. In a 53-patient, double-blind, placebo-controlled study evaluating the safety a...  

BALTIMORE, Feb 19, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced its financial results for the fourth quarter and twelve months ended December 31, 200...  

BALTIMORE, Feb 12, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced six-month interim results in its evaluation of CHONDROGEN(TM) for the regeneration of meniscus in the knee. A total of 55 patients were treated in the Phase I/II, double-blind study evaluating the safety and exploratory effectiveness of CHONDROGEN, a prepar...  

BALTIMORE, Jan 08, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today that PROCHYMAL(TM) has received Fast Track designation from the U.S. Food and Drug Administration, expediting the development of the stem cell treatment for Crohn's Disease that does not respond to standard therapies. Additionally, Osiris has receive...  

BALTIMORE, Dec 09, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announces follow-on data for its ongoing Phase II trial evaluating PROCHYMAL for the treatment of acute Graft vs. Host Disease. The study found that patients were twice as likely to have total clinical resolution of their disease when PROCHYMAL was added to steroid t...